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Abstract
Introduction: Acute liver failure (ALF) is a life-threatening multisystem illness complicated by multiple organ failure
(MOF) and haemodynamic disturbances. Morbidity and mortality remains high and various prognostic and scoring
models are in use to predict outcome. A recent observation in a large cohort of ALF patients suggested a
prognostic value of troponin I (cTnI) and its role as a marker of subclinical myocardial injury and outcome.
Methods: Data from consecutive ALF patients over a four-year period from January 2007 to March 2011 were
included. The aim of this study was to correlate any relationship that may exist between cTnI, mortality, severity of
illness and non-hepatic organ failure.
Results: A total of 218 subjects (age 36 (16 to 90) years, M:F 103:115) were studied, of which 136 had an elevated
cTnI > 0.05 μg/L. Higher organ failure scores were found with positive cTnI: APACHE II (19.5 (3 to 51) vs 14 (2 to
51), P = 0.001), APACHE III (81 (15 to 148) vs 59 (8 to 172), P = < 0.001) SOFA (15 (4 to 20) vs 13 (2 to 21), P =
0.027) and SAPS (48 (12 to 96) vs 34 (12 to 97), P = 0.001). Patients with positive cTnI had higher serum creatinine
(192 μmol/l (38 to 550) vs 117 μmol/l (46 to 929), P < 0.001), arterial lactate (0.25, P < 0.001) and a lower pH (-0.21,
P = 0.002). Also a higher proportion required renal replacement therapy (78% vs 60%, P = 0.006). Patients with
elevated cTnI more frequently required vasopressors-norepinephrine (73% vs 50%, P = 0.008). Elevated cTnI did not
predict outcome as effectively as other models (AUROC 0.61 (95% CI 0.52 to 0.68)).
Conclusions: More than 60% of ALF patients in this study demonstrated elevated cTnI. Despite a close correlation
with organ failure severity, cTnI was a poor independent predictor of outcome. cTnI may not represent true
myocardial injury and may be better viewed as a marker of metabolic stress.
Introduction
Acute liver failure (ALF) is a life-threatening multisystem
illness resulting from massive liver injury. The defining
clinical symptoms are coagulopathy and encephalopathy
occurring within days or weeks of the primary insult in
patients without pre-existing liver injury [1]. The heteroge-
neity of ALF in terms of underlying aetiology, its rarity and
the usually progressive, severe disease course with a high
fatality rate, result in limited controlled trial data being
available to guide optimal therapy [2]. Although significant
progress has been made over the last two decades in
managing ALF patients through improvements in inten-
sive care management, prognosis still remains poor in
defined subgroups without liver transplantation. The mul-
tisystem involvement of ALF along with the unpredictable
disease course poses unique challenges in managing these
patients [3].
ALF is frequently complicated by progressive haemody-
namic disturbances. There is evidence of peripheral vaso-
dilatation with resultant increase in cardiac output and
reduced systemic vascular resistance. Hypotension is a fre-
quent occurrence often requiring optimal fluid loading
and use of vasopressors. The pathogenesis of the haemo-
dynamic changes are incompletely characterised but are
likely multi-factorial, in part related to the systemic
inflammatory response syndrome (SIRS) evoked by the
liver necrosis and subsequently superimposed sepsis [4,5].
Although marked haemodynamic instability is a com-
mon finding in ALF, there is paucity of data in relation to
intrinsic myocardial function in this condition. This is
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partly explained by the demographics of patients with
ALF, in whom established risk factors for cardiovascular
disease are commonly absent.
A recent study suggested that myocardial injury is fre-
quently present in patients with ALF and demonstrated a
possible association between elevated troponin I (cTnI)
and outcome. The elevated cTnI was postulated to be due
to subclinical cardiac injury [6]. Troponin I is a well-estab-
lished, specific, and sensitive marker of myocardial injury,
with both diagnostic and prognostic value. It permits early
identification of patients at increased risk of death from
acute coronary syndrome [7-9]. However specificity is
reduced in certain conditions, such as sepsis, renal failure,
pulmonary embolic disease or acute stroke, all commonly
encountered in the critically ill, where cTnI levels can be
elevated in the absence of an acute coronary ischemic
event [9,10].
The American Acute Liver Failure Study Group focused
on the relationship of cTnI elevation and outcome, but
did not provide any information regarding results of diag-
nostic cardiac investigations such as echocardiography
and/or correlation with invasive haemodynamic data.
In the present study, we analysed cTnI along with inva-
sive haemodynamic and echocardiographic data in a large
cohort of patients presenting with acute liver failure. The
objectives of the study were to investigate the relationship
between cTnI, hospital mortality and cardiovascular para-
meters derived from invasive and non-invasive testing.
Materials and methods
All patients admitted to King’s College Hospital Liver
Intensive Therapy Unit (LITU) with a diagnosis of acute
liver failure (hyperacute liver failure, acute liver failure and
subacute liver failure) [11] between January 2007 and
March 2011 were evaluated for inclusion. The data was
collected from a specialist database (data collected by spe-
cialist audit staff and entered real time) within the Institute
of Liver Studies, King’s College Hospital (KCH). Ethical
approval for analysis and publication of the fully anon-
ymised audit dataset was given by the South East London
Research Ethics Committee (formerly known as King’s
College Hospital Research Ethics Committee). Patients
and their relatives were given the opportunity to have
their dataset removed from the database; none chose to do
so. Patients, who had standard blood tests including cTnI,
were included in the study. A total of 278 patients with
ALF were admitted during this period of which 218 (78%)
patients had cTnI tested.
Admission screening tests within the first 24 to 48 h
included viral serology, autoimmune screen, alpha fetopro-
tein, ferritin and copper in addition to full blood count,
electrolytes, liver and renal function tests, coagulation
screen (prothrombin time (PT) and international normal-
ised ratio (INR)), cTnI, arterial blood gas analysis and
arterial ammonia. All patients underwent 12-lead electro-
cardiogram regardless of troponin levels, on admission
and in case of abnormalities on continuous two-lead car-
diac monitoring on the Intensive Care Unit.
One hundred and forty-four patients underwent invasive
haemodynamic monitoring utilising the transpulmonary
thermodilution (TPTD) and arterial pulse contour techni-
ques (PiCCO™, Pulsion, Munich Germany), based on
clinical need and physician discretion. All patients who
required haemodynamic monitoring had a central venous
catheter placed in the internal jugular vein and an arterial
catheter inserted either in the femoral artery or axillary
artery. Cardiac index (CI), intrathoracic blood volume
index (ITBVI (a volumetric indicator of preload) and
extravascular lung water index (EVLWI) were the standard
haemodynamic variables recorded. The mean of three
measures of the cardiac variables on the day of cTnI test-
ing was calculated.
Transthoracic (TTE) or a transoesophageal echocar-
diogram (TEE) was performed in the event of ECG
abnormalities or raised cTnI. Echocardiograms were
also undertaken in those patients with haemodynamic
compromise with presence of shock or inappropriately
low cardiac output, or if central venous pressures were
significantly elevated suggesting right ventricular dys-
function. All TTE and TEE were performed by trained
cardiac technicians, cardiologists or an intensive care
specialist trained in perioperative/critical care echocar-
diography. Semi-quantitative assessment of left and right
ventricular function, presence of regional wall motion
abnormalities (RWMA), valvular pathology, relaxation
abnormalities, elevation of right ventricular systolic pres-
sure (RVSP) on Doppler examination and pericardial
effusion were reported. All haemodynamic measures
were made independently of the knowledge of cTnI
results.
The presence and severity of hepatic encephalopathy
was based on clinical assessment at the referring hospital
or following admission to this institution. Prospective data
including clinical variables for the determination of out-
come was collected. Scoring models describing the severity
of illness including Acute Physiology and Chronic Health
Evaluation II (APACHE), Simplified Acute Physiology
Score (SAPS) and Sequential Organ Failure Score (SOFA)
were recorded electronically on the day cTnI was tested.
Measurement of serum troponin I levels
Troponin I was analysed using Trop I ultra reagent sup-
plied by Siemens Healthcare Diagnostics (Siemens AG,
Munich, Germany). The ADVIA Centaur TnI-Ultra assay
is a three-site sandwich immunoassay using direct chemi-
luminometric technology. The European Society of Cardi-
ology and the American College of Cardiology recommend
using the 99th percentile as a cutoff value for troponin
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assays, above which any value is considered abnormal. For
the ADVIA Centaur assay, troponin levels > 0.4 μg/L are
taken to represent myocardial damage, levels > 1.5 μg/L
are suggestive of acute myocardial infarction. The mini-
mum detectable concentration for this assay is 0.006 μg/L
[10]. The coefficient of variation was 0.05. Patients with
abnormal cTnI were divided into troponin-positive (> 0.05)
or troponin-negative (< 0.05), cTnI-high (> 0.7) or cTnI-
low groups (< 0.21) based on the tertiales of the distribu-
tion of cTnI results to further assess the impact of cTnI on
echocardiographically derived ventricular function given
that all patients with a positive troponin underwent echo-
cardiographic examination.
Statistical analysis
Assuming an effect size of 0.1, alpha of 0.05 and power of
80% to detect predictor independence from a model using
15 predictors, 200 sets of patient data were required. Data
is reported as mean (SD) and median (range) and statisti-
cal testing utilised Student’s t test/Mann Whitney U test/
ANOVA/Kruskal-Wallis as appropriate following normal-
ity testing. Categorical data were compared using the c2
test. Logistic regression and area under the receiver oper-
ating characteristic curve (AUROC) was performed to
assess the effect of measured variables on outcome. Statis-
tical significance was defined at the 95% level. Statistical
analysis was performed within the Statistics Package for
the Social Sciences (SPSS, version 17.0 SPSS Inc., Chicago,
IL, USA) and MedCalc version 11.4.4 (MedCalc Software,
Mariakerke, Belgium).
Results
Demographic data of the study population is shown in
Table 1 and 2. A total of 218 (M 103 (47%): F 115(53%))
patients who fulfilled criteria for acute liver failure were
enrolled from January 2007 to March 2011. Median age
was 36 years (16 to 90) and 136 (62%) patients had an
elevated cTnI > 0.05 μg/L (positive cTnI) on admission.
Acetaminophen intoxication was the most common
aetiology for ALF with hypoxic hepatitis, viral infections
and recreational drugs (cocaine (7), ecstasy (5)) account-
ing for the remaining cases. Non-acetaminophen drug-
induced liver failure was the most common aetiology
among the subacute liver failure (SALF) group followed
by indeterminate and autoimmune hepatitis.
Troponin-I
Patients in both the acetaminophen and non-acetami-
nophen-induced ALF presented with a wide range of
abnormal troponin I levels ranging from 0.05 to 50,
very high levels were more frequently observed in indi-
viduals with recreational drug-induced liver injury.
Individuals with positive cTnI were older and had
more severe organ failure. The median organ failure
scores found in patients with positive cTnI were:
APACHE II (19.5 (3 to 51) vs 14 (2 to 51), P = 0.001),
SOFA (15 (4 to 20) vs 13 (2 to 21), P = 0.027). Patients
with positive cTnI had higher median serum creatinine
levels (192 (38 to 550) μmol/l vs 117 (46 to 929)
μmol/l, P < 0.001, MWU test) and more frequently
required renal replacement therapy (49% vs 22%, P =
0.006 c2 test). Troponin I elevation correlated signifi-
cantly with pH (-0.21, P = 0.002) (r values), hepatic
encephalopathy grade (0.25, P < 0.001) and arterial lac-
tate (0.25, P < 0.001).
No difference in haemodynamic parameters were
noted between the cTnI-negative and -positive groups
for mean arterial pressure ((MAP) 70 (50 to 124) vs 70
(45 to 180); P = 0.221] or cardiac index (4.3 (2.0 to 6.5)
vs 4.2 (2.9 to 6.9); P = 0.511). However patients with
elevated cTnI required more vasopressor support-nore-
pinephrine (45% vs 19%, P = < 0.008) Table 1. Subjects
with elevated cTnI had higher creatinine kinase levels
(CK) (292 (6 to 37840) IU/L vs 81 (14 to 1417) IU/L
(P = < 0.001)) Table 1.
CTnI and electrocardiogram
Electrocardiographic abnormalities were identified in 43
patients: 31 (cTnI-positive) and 12 (cTnI-negative) P =
0.712). Non-specific ST and T wave changes were diag-
nosed in 11 patients. Ten patients had either ST depres-
sion or elevation: Five showed evidence of ST depression,
global ST changes were seen in two patients, one with
pre-existing ischaemic heart disease and the other post
cardiac arrest and three had ST elevation. T wave inver-
sion was found in ten patients and eight patients had
rhythm disturbances: atrial fibrillation was diagnosed in
six; one patient had a re-entrant tachycardia and one
showed atrial ectopics and right bundle branch block.
Two patients were diagnosed with left bundle branch
block. No evidence of QT prolongation was observed in
this cohort.
CTnI and echocardiography
One hundred and forty-four patients underwent echo-
cardiography; 100 in the cTnI-positive group (TI-pos)
and 44 in the cTnI-negative group (TI-neg). Thirteen
patients were diagnosed with a small not haemodynami-
cally significant pericardial effusion Table 2.
CTnI and regional wall motion abnormality (RWMA)
RWMA were evident in 3/100 (3%) in the cTnI-positive
group and 1/44 (2%) in the cTnI-negative group. There
was no statistically significant association identified in
regard of RWMA between cTnI-positive/negative
patients (P = 0.752).
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> 0.05, N = 136
Troponin- negative
< 0.049, N = 82
P value
Age 36 (16-90) 39 (16-80) 33.5 (16-90) 0.059
Gender (M:F) 103:115 (47%:53%) 67:69 36:46 0.529
Spontaneous survival (Y:N) 106:112 61:75 45:37 0.195
ALF/SALF 178:40 116:20 62:20 0.170
AST 2779 (22-31320) 3154 (38-20000) 2047 (22-31320) 0.0273
Bilirubin 96 (6-1265) 83 (6-739) 122 (9-1265) 0.245
Albumin 30 (16-49) 31 (18-39) 31 (16-49) 0.851
Urea 6.4 (1.5-19.2) 8.8 (2.3-19) 5.2 (1.5-15.9) 0.109
Creatinine 187 (38-929) 192 (38-550) 117 (46-929) < 0.001
INR 4.4 (1-16) 4.3 (1-15.7) 4.4 (1.2-16) 0.649
pH 7.4 (6.9-7.5) 7.4 (6.9-7.5) 7.4 (7.23-7.5) 0.009
Lactate 2.2 (0.3-24) 2.4 (0.7-24) 2.0 (0.3-11) 0.036
CK 175 (6-37840) 292 (6-37840) 81 (14-1417) < 0.001
CVVHF 155:63 106:30 49:33 0.006
Inotropes (Y:N) 140:77 99:36 41:41 0.008
NH4 89 (12-346) 88 (12-346) 97 (19-285) 0.545
HE grade 3 (1-4) 4 (1-4) 3 (1-4) 0.017
Heart rate 98 (45-170) 98 (45-160) 99 (50-170) 0.346
MAP 77 (45-180) 70 (50-124) 70 (45-180) 0.308
CVP 13 (4-26) 14 (5-26) 12 (4-22) 0.005
SVO2 80 (55-94) 80 (55-93) 80 (60-94) 0.365
Invasive ventilation 147:71 106:30 41:41 < 0.001
MELD 39 (11-40) 40 (11-40) 37 (12-40) 0.135
APACHE 2 18 (2-51) 19.5 (3-51) 14 (2-51) 0.001
SAPS 46 (12-97) 48 (12-96) 34 (12-97) 0.001
SOFA 14 (2-21) 15 (4-20) 13 (2-21) 0.027
Mann Whitney U test or c2 test performed as appropriate. ALF, acute liver failure; APACHE, Acute Physiology and Chronic Health Evaluation; AST, aspartate
transaminase; CK, creatinine kinase; CVP, central venous pressure; CVVHF, continuous venovenous haemofiltration; HE, hepatic encephalopathy; INR. international
normalised ratio; MAP, mean arterial pressure; MELD, model for end stage liver disease; NH4, ammonia; SALF, subacute liver failure; SAPS, Simplified Acute
Physiology Score; SOFA, Sequential Organ Failure Assessment; SV02, central venous saturation.




Troponin positive Troponin negative P value
Echo data available (Y:N) 144:74 100:36 44:38 0.003
N = 144
Abnormal ECG (Y:N) 43:101 31:69 12:32 0.712
Arrhythmia (Y:N) 7:137 7:93 0:44 0.167
LVF 16:128 15:85 1:43 0.051
RHF 8:136 8:92 0:44 0.124
Pericardial effusion (Y:N) 13:131 9:91 4:40 0.756
High PA pressures (Y:N) 8:136 7:93 1:43 0.576
RWMA (Y:N) 4:140 3:97 1:43 0.752
CI 4.3 (2-6.9) 4.3 (2-6.5) 4.2 (2.9-6.9) 0.511
ITBVI 785 (426-1366) 763 (426-1366) 735 (488-1186) 0.136
EVLWI 9.5 (4.6-34) 9 (4-34) 9 (6-18) 0.882
CI, cardiac index; EVLWI, extravascular lung water index; ITBVI, intrathoracic blood volume index; LVF, left ventricular failure; PA, pulmonary artery; RHF, right heart
failure; RWMA, regional wall motion abnormality.
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cTnI and global left ventricular dysfunction (LVD)
LVD was observed in 15% of patients with a positive
cTnI (15/100). Left ventricular dysfunction in the cTnI-
positive group was more pronounced in those indivi-
duals with pre-existing cardiac disease such as ischaemic
heart disease, cardiomyopathy and post cardiac arrest
when compared to the cTnI-negative group (2%, 1/43).
A borderline statistical association was noted between
cTnI positivity and LVD (15/85 vs 1/43, P = 0.053, c2
test).
Predictors of poor outcome in ALF/SALF
Median cTnI levels measured 0.08 μg/L (0 to 50) in
those who survived and 0.18 μg/L (0 to 50) in those
who either died or were transplanted; P = 0.046 (Mann
Whitney U test). There was no difference in troponin
positivity between the ALF (116/178) and SALF (20/40)
cohort (P = 0.107, c2 test), cTnI was not associated
with poor outcome on either univariate or multivariate
analysis (Table 3).
Independent prognostic significance was neither found
when patients were subgrouped into those with hypoxic
aetiology (P = 0.341) nor with regards to the presence
or absence of raised pulmonary artery pressures (P =
0.756).
Age, aetiology of liver disease, bilirubin, INR, lactate,
hepatic encephalopathy, mean arterial blood pressure,
continuous venovenous haemodiafiltration (CVVHF),
vasopressor use and fraction of inspired oxygen (FiO2)
requirements were found to be associated with poor
outcome on univariate analysis. However, on multivari-
ate analysis only bilirubin (odds ratio (OR) 1.003, confi-
dence interval (CI) 1.000 to 1.006, P = 0.039), INR (OR
1.263, CI 1.096 to 1.455, P = 0.001), lactate (OR 1.547,
CI 1.137 to 2.105, P = 0.005), and hepatic encephalopa-
thy grade (OR 3.293, CI 1.895 to 5.723, P = < 0.001)
along with organ failure scores were identified as inde-
pendent predictors of poor outcome in this group
(Table 4).
AUROC analysis demonstrated the composite multi-
variate model that is, bilirubin, lactate, INR and hepatic
encephalopathy grade (AUROC 0.89 (0.83 to 0.94)) to
be the best predictor of outcome in ALF group followed
by model for end-stage liver disease (MELD) (0.76 (0.68
to 0.83)) in this mixed cohort of patients (acetamino-
phen and non-acetaminophen). Despite a close correla-
tion with organ failure severity, AUROC analysis
confirmed that cTnI did not predict poor outcome
(AUROC 0.61 (0.52 to 0.68)) (Figure 1).
Discussion
Elevation of cTnI in patients presenting with either
ALF/SALF is not uncommon as demonstrated in the
present study as well as previously by Parekh et al [6].
A positive correlation between cTnI elevation and vaso-
pressor requirements, presence of acute kidney injury
and organ failure scores was found; cardiac dysfunction
on echocardiography or low-flow state on invasive hae-
modynamic monitoring was not more frequent in cTnI-
positive patients. Troponin-I elevation observed in ALF/
SALF is likely to represent an epiphenomenon of multi-
organ failure rather than myocardial injury. Despite







Age 34 (16-90) 38 (17-80) 0.089
Gender (M:F) 51:55 52:60 0.909
ALF/SALF 99:7 33:79 < 0.001
Troponin 0.08 (0-50) 0.18 (0-50) 0.046
AST 2969 (22-31320) 2197 (24-20000) 0.4122
Bilirubin 83 (6-1265) 123 (16-739) 0.011
Albumin 32 (18-49) 30 (16-38) 0.312
Urea 7.2 (2.5-19.2) 4.5 (1.5-17.9) 0.127
Creatinine 166 (38-929) 170 (46-404) 0.867
INR 3.2(1-11) 5.5 (1.5-16) < 0.001
pH 7.4 (7.17-7.5) 7.4 (6.9-7.51) 0.074
Lactate 1.85 (0.7-24) 2.6 (0.3-19) < 0.001
CK 151 (14-36985) 258 (6-3784) 0.210
CVVHF 65:41 90:22 0.003
Inotropes (Y:N) 48:57 92:20 < 0.001
NH4 75 (18-346) 97 (12-285) 0.001
HE Grade 2 (1-4) 4 (1-4) < 0.001
Heart rate 93 (45-170) 100 (50-160) 0.051
MAP 77 (50-180) 68 (45-129) < 0.001
CVP 12 (4-23) 14 (7-26) 0.030
SVO2 79 (60-94) 80 (55-93) 0.355
CI 4.1 (2-6.9) 4.4 (2-6.7) 0.309




pO2 11.6 (7.4-26) 10.6 (5.9-19) 0.023
FiO2 0.3 (0.21-1) 0.35 (0.21-1) < 0.001
MELD 35 (11-40) 40 (15-40) < 0.001
APACHE 2 15 (2-43) 21 (3-51) < 0.001
SAPS 36 (12-94) 51 (12-97) < 0.001
SOFA 12.5 (2-19) 15 (4-21) < 0.001
There was no difference in troponin positivity between the ALF (116/178) and
SALF (20/40) cohort (P = 0.107, c2 test), neither did troponin I predict poor
outcome in either ALF or SALF cohorts so they were examined together for
determinants of outcome. ALF, acute liver failure; APACHE, Acute Physiology
and Chronic Health Evaluation; AST, aspartate transaminase; CK, creatinine
kinase; CVP, central venous pressure; CVVHF, continuous venovenous
haemofiltration; FiO2, fraction of inspired oxygen; HE, hepatic encephalopathy;
INR. international normalised ratio; MAP, mean arterial pressure; MELD, model
for end stage liver disease; NH4, ammonia; pO2, partial pressure of oxygen;
SALF, subacute liver failure; SAPS, Simplified Acute Physiology Score; SOFA,
Sequential Organ failure Assessment; SV02, central venous saturation.
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previous association between positive cTnI with poor
outcome our data is not supportive of this.
Cardiac isoforms of TI (cTnI) and troponin T (cTnT)
are highly sensitive and specific markers of myocardial
injury in acute coronary syndromes [12]. However, cTnI
elevations may be seen in other disease processes of car-
diac and non-cardiac origin including myocarditis, pul-
monary embolic disease, septic shock, renal failure and
following cardiotoxic chemotherapy [13-15]. Troponin
release from the myocardium into the circulation is
Table 4 Results of multivariate analysis of predictors of outcome.
Variable Odds ratio 95% CI P value Odds ratio 95%CI P value
Age 1.016 0.998-1.034 0.077
Gender (M:F) 0.934 0.549-1.591 0.803
Troponin 1.032 0.974-1.094 0.281
Troponin positive 1.493 0.862-2.593 0.152
Troponin high 1.674 0.947-2.761 0.077
LVF (Y/N) 0761 0.271-2.174 0.617
ALF/SALF 5.907 2.481-14.064 < 0.001 - - -
Ischaemic Aetiology 0.572 0.181-1.808 0.341
AST 1.000 0.999-1.000 0.2379
Peak AST 1.000 0.999-1.000 0.857
Bilirubin 1.002 1.000-1.004 0.029 1.003 1.000-1.006 0.039
Albumin 0.953 0.872-1.042 0.289
Urea 0.936 0.817-1.072 0.341
Creatinine 0.998 0.996-1.007 0.168
CVVHF 2.580 1.400-4.74 0.001
INR 1.264 1.154-1.385 < 0.001 1.263 1.096-1.455 0.001
pH 0.037 0.001-1.407 0.064
Lactate 1.296 1.132-1.481 < 0.001 1.547 1.137-2.105 0.005
Heart rate 1.019 1.000-1.021 0.046
MAP 0.967 0.952-0.982 < 0.001
CI 1.127 0.784-1.618 0.516
ITBVI 0.996 0.997-1.001 0.708
EVLWI 1.009 0.921-1.105 0.840
CVP 1.108 1.009-1.214 0.025
SVO2 1.015 0.965-1.065 0.546
Inotropes (Y:N) 5.463 2.946-10.182 < 0.001
CK 1.000 0.999-1.000 0.596
Invasive ventilation 2.234 1.250-3.999 0.006
pO2 0.897 0.815-0.984 0.018
FiO2 8.392 1.502-46.79 0.009
pO2/FiO2 ratio 0.946 0.946-0.982 < 0.001
NH4 1.007 1.002-1.013 0.005
HE Grade 2.471 1.812-3.654 < 0.001 3.293 1.895-5.723 < 0.001
MELD 1.130 1.071-1.198 < 0.001 -
APACHE 2 1.081 1.042-1.124 < 0.001 -
SAPS 1.038 1.021-1.055 < 0.001 -
SOFA 1.168 1.088-1.254 < 0.001 -
The multivariate analysis is for the ALF cohort only given the low numbers of SALF patients. The independent multivariate predictors are on the right. This model
would correctly classify 80% of patients with an AUROC of 0.84 (0.79 to 0.89, P < 0.001). ALF, acute liver failure; APACHE, Acute Physiology and Chronic Health
Evaluation; AST, aspartate transaminase; CI, confidence interval; CK, creatinine kinase; CVP, central venous pressure; CVVHF, continuous venovenous
haemofiltration; FiO2, fraction of inspired oxygen; HE, hepatic encephalopathy; INR. international normalised ratio; MAP, mean arterial pressure; MELD, model for
end stage liver disease; NH4, ammonia; pO2, partial pressure of oxygen; SALF, subacute liver failure; SAPS, Simplified Acute Physiology Score; SOFA, Sequential
Organ Failure Assessment; SV02, central venous saturation.
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thought to be either due to transient leakage as seen in
reversible ischemia or continuous resulting from irreversi-
ble ischaemic damage [14-16]. Proposed mechanisms for
troponin release in critically ill patients include focal ische-
mia, often triggered by massive sympathomimetic
response, direct cardiac myocytotoxic effects of endotox-
ins, cytokines or reactive oxygen radicals due to infectious
process [15-18]. In addition, it has been postulated that
intracellular pathways may be triggered in critically ill
patients resulting in degradation of free troponin to lower
molecular weight fragments, which are released because of
increased cell membrane permeability [16-18].
Several clinical and experimental studies have demon-
strated a positive correlation between elevated troponin in
sepsis/critical illness and unfavourable outcome. Assess-
ment of cardiac function in sepsis and critical illness may
be challenging as most of the cardiac contractility indices
are affected by peripheral vasomotor tone and changes in
loading conditions. In addition, catecholamine stress
observed in sepsis may stimulate the myocardium and
may mask myocardial depression [19]. These limitations
along with the absence of a gold standard technique to
assess myocardial performance have led to the utilisation
of cardiac biomarkers such as troponin as sensitive prog-
nostic markers of subclinical myocardial injury.
We found that 62% of patients with ALF/SALF had
elevated cTnI. The reasons for this are likely to be
multifactorial. Abnormal cTnI levels correlated closely
with organ failure scores, renal failure and inotropic use.
As expected, very high values of cTnI in our series were
more often seen in those individuals presenting with
recreational drug overdose that is, cocaine and ecstasy
either in isolation or with concomitant use of acetami-
nophen. This may be due to direct cardiotoxic effects
and or the severe metabolic derangement and high inci-
dence of renal failure seen in these individuals.
High cardiac output associated with generalised vasodi-
latation is common in ALF [20]. It has been proposed
that the high cardiac output state increases cardiac work-
load thereby increasing oxygen demand. Tachycardia can
further compromise coronary perfusion due to the
reduced diastolic time. In addition, the aggressive use of
inotropic and vasopressor agents to maintain adequate
end organ perfusion and systemic oxygen delivery may
increase the incidence of cardiovascular complications.
Comparison of invasive haemodynamic parameters did
not demonstrate a significant difference between tropo-
nin-positive and -negative patients. This has to be inter-
preted with caution given the higher vasopressor and
inotrope requirements in the cTnI-positive group.
Echocardiography is a readily available monitoring tool
to assess myocardial performance during critical illness. A
negative correlation between left ventricular ejection frac-
tion and positive cTnI, either as a one-off measurement or
performed serially has been reported in septic patients
[21-24]. Myocardial depression characterised by reversible
biventricular dilation, decreased systolic contractile func-
tion, and decreased response to both fluid resuscitation
and inotropic therapy has been described in septic shock
[25], but data in ALF is lacking.
LVD in our cohort was more often seen in patients with
high troponin levels and in the context of hypoxic hepati-
tis due to pre-existing cardiac conditions. However, we did
not observe any evidence of biventricular dilatation on
echocardiography. In contrast to the sepsis literature [26],
the incidence of RWMA did not correlate with cTnI levels.
The lower scan frequency among the cohort with normal
troponin and ECG findings is a consequence of ECHO
being undertaken more often in patients with haemody-
namic compromise where there was a clinical suspicion of
left, right or biventricular dysfunction.
Troponin has been used has a prognostic marker in cri-
tical illness. Its role as an independent predictor of out-
come has been debated in various clinical scenarios and
studies. Among selected groups with sepsis, troponin ele-
vation has been shown to be related to the severity of ill-
ness whereas in unselected critically ill patients, mortality
among troponin-positive group is higher irrespective of
the cause of troponin increase [23-29]. In our study, cTnI
levels were lower among survivors when compared to
those who either died or underwent transplantation;
Figure 1 Comparison of outcome prediction in this cohort
between troponin I, MELD and a composite multivariate model
using the independent variables from Table 3. Troponin I
(AUROC 0.61 (0.52 to 0.68)); MELD (0.76 (0.68 to 0.83); Composite
model (AUROC 0.89 (0.83 to 0.94)), P < 0.001 for all comparisons.
AUROC, area under the receiver operating curve; MELD, model for
end-stage liver disease.
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however neither uni- nor multivariate analysis showed a
significant correlation with outcome.
Conclusions
Troponin I elevation in critical illness is common and
multifactorial. In this large cohort of patients with ALF
and SALF, cTnI elevation correlated poorly with func-
tional cardiac abnormalities observed during echocardio-
graphic and invasive haemodynamic studies. Although
higher cTnI levels were observed in patients with higher
severity of illness, its value as an independent predictor
of outcome was poor. Positive cTnI in this cohort is
likely to represent an epiphenomenon of multiple organ
failure (MOF).
Key Messages
• cTnI elevation observed in ALF/SALF may not
represent true myocardial injury and may be better
viewed as a marker of metabolic stress.
• cTnI is not associated with directly measured hae-
modynamic abnormalities in ALF patients.
• Despite previous observations suggesting positive
cTnI being associated with an independent risk of
poor outcome, these data suggest cTnI positivity is
an epiphenomenon of MOF that may not contribute
independently to poor outcome in this cohort.
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